#United States #New York #Proton Therapy #New York Proton Center #PTCOG 64

New York Proton Center Advances in Proton Therapy

The New York Proton Center (NYPC) is at the forefront of proton therapy innovation, and it is excited to present its latest research at the 64th Annual Conference of the Particle Therapy Cooperative Group (PTCOG 64) scheduled from June 8–13, 2026, in Deauville, France. This prestigious event gathers over 1,000 professionals, including radiation oncologists, medical physicists, and researchers, to explore the newest findings in particle therapy, particularly proton beam technology.

Showcasing Extensive Research

NYPC's contribution to PTCOG is substantial, with more presentations than any other single-site proton center. The focus of these presentations includes various cancer types such as spinal, uterine, cervical, thoracic, gastrointestinal, breast, central nervous system (CNS), and head and neck cancers. One of the standout features of this year’s presentations is the introduction of ultra-high dose rate FLASH therapy, which has transformative potential for patient care.

Dr. Charles B. Simone II, the Chief Medical Officer of NYPC, leads the charge with sessions highlighting the effectiveness of proton therapy. He emphasizes that cancer management should not only aim to eradicate disease but also allow patients to maintain a quality lifestyle during and after treatment. NYPC’s extensive data presentation spans over 15 sessions, showcasing compelling results and innovations in cancer treatment through proton therapy.

Innovations in Treatment Technology

The technology at NYPC includes sophisticated pencil beam scanning that precisely targets tumors while significantly reducing radiation exposure to surrounding healthy tissues and important organs. This capability distinguishes proton therapy from conventional photon therapy, allowing for targeted treatment that minimizes side effects, presenting a safer alternative for various cancer profiles.

Research indicates that for primary spinal tumors, proton therapy can achieve favorable local control without extreme toxicity. Dr. Arpit Chhabra, a radiation oncologist at NYPC, leads multiple sessions that concentrate on the application of proton therapy in spinal and CNS tumors, supporting its use as a primary treatment strategy for suitable patients.

Furthermore, sessions led by Dr. Kristin Hsieh will present findings on gynecologic cancers, particularly focusing on uterine and cervical cancer cases with proton therapy treatment, marking some of the largest reported patient cohorts.

Commitment to Patient-Centric Care

The collaboration between NYPC and renowned institutions such as Memorial Sloan Kettering Cancer Center augments the quality and reach of cancer care. By effectively implementing clinical trials and pioneering research, NYPC is pushing the boundaries of what is possible with proton therapy.

Innovations such as FLASH therapy, which employs ultra-high dose protons, could spare healthy tissues while still targeting tumors effectively. Meanwhile, GRID therapy, which utilizes a pattern of high-dose and lower-dose radiation, further underlines NYPC's commitment to minimizing treatment-related complications.

The leadership at NYPC, including CEO Christopher Panczner, reflects on this milestone, noting that the data presented at PTCOG 64 not only showcases NYPC's advancements but also affirms its dedication to patient well-being. The center aims to expand access to treatment while fostering relationships with patients who contribute to clinical research.

Conclusion

The New York Proton Center’s presentation at PTCOG 64 reaffirms its position as a leader in the field of proton therapy. This innovation-driven commitment to patient care and advancement in cancer treatment technologies sets a foundation for the future of cancer therapies. As NYPC continues to demonstrate leadership through presentation and research, it simultaneously reinforces the message of hope for patients navigating through cancer treatment, making a significant difference in their lives.

For more information on NYPC and its contributions to cancer treatment, visit nyproton.com.